BridgeBio Pharma, Inc. (BBIO)
NASDAQ · Healthcare
BridgeBio Pharma, Inc. EBITDA 2019–2025
BridgeBio Pharma, Inc. annual/quarterly ebitda history and growth rate from 2019 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- BridgeBio Pharma, Inc. ebitda for the quarter ending March 31, 2026 was -104.8 M, a 1.63% increase year-over-year.
- BridgeBio Pharma, Inc. ebitda for the twelve months ending March 31, 2026 was -330.4 M.
- BridgeBio Pharma, Inc. annual ebitda for 2025 was -518.0 M, a 11.74% decrease from 2024.
- BridgeBio Pharma, Inc. annual ebitda for 2024 was -586.9 M, a 2.33% decrease from 2023.
- BridgeBio Pharma, Inc. annual ebitda for 2023 was -600.9 M, a 18.88% increase from 2022.
- BridgeBio Pharma, Inc. annual ebitda for 2022 was -505.4 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BridgeBio Pharma, Inc. EBITDA — FAQ
BridgeBio Pharma, Inc. (BBIO) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BBIO's ebitda history?
The chart and table above show BridgeBio Pharma, Inc.'s ebitda by year and by quarter, including the growth rate.